Allergic conjunctivitis and H1 antihistamines

Journal of Investigational Allergology and Clinical Immunology

Volumn 19, Issue SUPPL. 1, 2009, Pages 11-18

  Del Cuvillo, A ^a   Sastre, J ^b,c   Montoro, J ^d   Jauregui I ^e   Davila I ^f   Ferrer, M ^g   Bartra, J ^c,h   Mullol, J ^c,i   Valero, A ^c,h  

^a Clinica Dr Lobaton   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL DE LA PLANA   (Spain)

^e HOSPITAL DE BASURTO   (Spain)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Allergic conjunctivitis; ocularallergy; oral antihistamines; topic alantihistamines

Indexed keywords

ANTAZOLINE; ANTIHISTAMINIC AGENT; ARTIFICIAL TEAR; AZELASTINE; CETIRIZINE; CHEMOKINE RECEPTOR ANTAGONIST; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DESLORATADINE; EBASTINE; EMEDASTINE; EPINASTINE; FEXOFENADINE; KETOROLAC; KETOTIFEN; LEVOCABASTINE; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; NEDOCROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; OLOPATADINE; PHENIRAMINE; PLACEBO; RUPATADINE; VASOCONSTRICTOR AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST;

ALLERGIC CONJUNCTIVITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATARACT; CHROMOSOME 16; CHROMOSOME 17; CHROMOSOME 5; CHROMOSOME 6; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONJUNCTIVAL IRRITATION; CORNEA ULCER; DRUG ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRY EYE; ENVIRONMENTAL FACTOR; EYE ALLERGY; EYE IRRITATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GLAUCOMA; HUMAN; KERATOCONJUNCTIVITIS; LACRIMATION; NONHUMAN; OCULAR PRURITUS; PATHOPHYSIOLOGY; PREVALENCE; REBOUND; RHINOCONJUNCTIVITIS; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; REVIEW; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; CLINICAL TRIALS AS TOPIC; CONJUNCTIVITIS, ALLERGIC; HISTAMINE H1 ANTAGONISTS; HUMANS;

EID: 64349116682     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC, Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;1 13: 832-836.
2. Navarro A, Rinitis. In: Hernandez AP ed. Alergológica 2005 Factores epidemiológicos, clínicos y socioeconómicos de las enfermedades alérgicas en España. Madrid: Luzan 5 S.A. de ediciones, 2006:107-132.
3. Bartra J, Actualización en Alergia Ocular. Barcelona: Editorial Glossa, 2003.
4. Ono SJ, Abelson MB, Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005;115: 118-122.
5. Bonini S, LambiaseA, Genetics of ocular allergy.Acta Ophthalmol Scand Suppl 1999: 31-32.
6. Nishimura A, Campbell-Meltzer RS, Chute K, Orrell J, Ono SJ, Genetics of allergic disease: evidence for organ-specific susceptibility genes. Int Arch Allergy Immunol 2001;124: 197-200.
7. Bundoc VG, Keane-Myers A, Animal models of ocular allergy. Curr Opin Allergy Clin Immunol 2003;3: 375-379.
8. Miyazaki D, Liu G, Clark L, Ono SJ, Prevention of acute allergic conjunctivitis and late-phase inflammation with immunostimulatory DNA sequences. Invest Ophthalmol Vis Sci 2000;41: 3850-3855.
9. Ohbayashi M, Manzouri B, Flynn T, Toda M, Ikeda Y, Nakamura T, Ono SJ, Dynamic changes in conjunctival dendritic cell numbers, anatomical position and phenotype during experimental allergic conjunctivitis. Exp Mol Pathol 2007;83: 216-223.
10. Nakamura T, Toda M, Ohbayashi M, Ono SJ, Detailed criteria for the assessment of clinical symptoms in a new murine model of severe allergic conjunctivitis. Cornea 2003;22: S13-18.
11. Nakamura T, Ohbayashi M, Toda M, Hall DA, Horgan CM, Ono SJ, A specific CCR3 chemokine receptor antagonist inhibits both early and late phase allergic inflammation in the conjunctiva. Immunol Res 2005;33: 213-221.
12. Spangler DL, Abelson MB, Ober A, Gotnes PJ, Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin Ther 2003;25: 2245-2267.
13. Crampton HJ, Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Clin Ther 2003;25: 1975-1987.
14. Ousler GW, 3rd, Workman DA, Torkildsen GL, An open label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther 2007;29: 611-616.
15. Greiner JV, Udell IJ, A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 2005;27: 568-577.
16. Pipkorn U, Bende M, Hedner J, Hedner T, A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis. Allergy 1985;40: 491-496.
17. Yanni JM, Stephens DJ, Parnell DW, Spellman JM, Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol 1994;10: 665-675.
18. Ciprandi G, Buscaglia S, Catrullo A, Pesce G, Fiorino N, Montagna P, Bagnasco M, Canonica GW, Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy 1997;27: 182-191.
19. Kidd M, McKenzie SH, Steven I, Cooper C, Lanz R, Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. Br J Ophthalmol 2003;87: 1206-1211.
20. Abelson MB, A review of olopatadine for the treatment of ocular allergy. Expert Opin Pharmacother 2004;5: 1979-1994.
21. Brodsky M, Berger WE, Butrus S, Epstein AB, Irkec M, Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen challenge model. Eye Contact Lens 2003;29: 113-116. 22. Owen CG, Shah A, Henshaw K, Smeeth L, Sheikh A, Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. Br J Gen Pract 2004;54: 451-456.
22. D'Arienzo PA, Leonardi A, Bensch G, Randomized, double- masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 2002;24: 409-416.
23. Spangler DL, Bensch G, Berdy GJ, Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 2001;23: 1272-1280.
24. Aguilar AJ, Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand Suppl 2000: 52-55.
25. Avunduk AM, Tekelioglu Y, Turk A, Akyol N, Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute- controlled trial. Clin Ther 2005;27: 1392-1402.
26. Leonardi A, Zafirakis P, Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference. Curr Med Res Opin 2004;20: 1167-1173.
27. Lanier BQ, Finegold I, D'Arienzo P, Granet D, Epstein AB, Ledgerwood GL, Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr Med Res Opin 2004;20: 1227-1233.
28. Abelson MB, Greiner JV, Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Curr Med Res Opin 2004;20: 1953-1958.
29. Verin P, Easty DL, Secchi A, Ciprandi G, Partouche P, Nemeth Wasmer G, Brancato R, Harrisberg CJ, Estivin-Ebrardt C, Coster DJ, Apel AJ, Coroneo MT, Knorr M, Carmichael TR, Kent-Smith BT, Abrantes P, Leonardi A, Cerqueti PM, Modorati G, Martinez M, Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. Am J Ophthalmol 2001;131: 691-698.
30. Swamy BN, Chilov M, McClellan K, Petsoglou C, Topical non- steroidal anti-inflammatory drugs in allergic conjunctivitis: meta-analysis of randomized trial data. Ophthalmic Epidemiol 2007;14: 311-319.
31. Discepola M, Deschenes J, Abelson M, Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. Acta Ophthalmol Scand Suppl 1999: 43-46.
32. Deschenes J, Discepola M, Abelson M, Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol Scand Suppl 1999: 47-52.
33. Leurs R, Church MK, Taglialatela M, H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32: 489-498.
34. del Cuvillo A, Mullol J, Bartra J, Davila I, Jauregui I, Montoro J, Sastre J, Valero AL, Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol 2006;16 Suppl 1: 3-12.
35. de Blic J, Wahn U, Billard E, Alt R, Pujazon MC, Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol 2005;16: 267-275.
36. Potter PC, Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: a double-blind, placebo-controlled randomized clinical trial. Ann Allergy Asthma Immunol 2005;95: 175-180.
37. Leynadier F, Mees K, Arendt C, Pinelli ME, Efficacy and safety of levocetirizine in seasonal allergic rhinitis. Acta Otorhinolaryngol Belg 2001;55: 305-312.
38. Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J, Van Cauwenberge PB, Van Hammee G, Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004;114: 838-844.
39. Pradalier A, Neukirch C, Dreyfus I, Devillier P, Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis. Allergy 2007;62: 1331-1334.
40. Kim K, Sussman G, Hebert J, Lumry W, Lutsky B, Gates D, Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2006;96: 460-465.
41. Rossi GA, Tosca MA, Passalacqua G, Bianchi B, Le Grazie C, Canonica GW, Evidence of desloratadine syrup efficacy and tolerability in children with pollen-induced allergic rhinitis. Allergy 2005;60: 416-417.
42. Martinez-Cocera C, De Molina M, Marti-Guadano E, Pola J, Conde J, Borja J, Perez I, Arnaiz E, Izquierdo I, Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J Investig Allergol Clin Immunol 2005;1 5: 22-29.
43. Saint-Martin F, Dumur JP, Perez I, Izquierdo I, A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol 2004;14: 34-40.
44. Ratner P, Falques M, Chuecos F, Esbri R, Gispert J, Peris F, Luria X, Rosales MJ, Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis. Int Arch Allergy Immunol 2005;138: 312-318.
45. Bousquet J, Gaudano EM, Palma Carlos AG, Staudinger H, A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. Multicentre Study Group. Allergy 1999;54: 562-568.
46. Falliers CJ, Brandon ML, Buchman E, Connell JT, Dockhorn R, Leese PT, Miller J, Wasserman SI, Zeterberg JM, Altman R,et al., Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann Allergy 1991;66: 257-262.
47. Mansmann HC, Jr., Altman RA, Berman BA, Buchman E, Dockhorn RJ, Leese PT, Love SJ, Middleton E, Jr., Efficacy and safety of cetirizine therapy in perennial allergic rhinitis. Ann Allergy 1992;68: 348-353.
48. Masi M, Candiani R, van de Venne H, A placebo-controlled trial of cetirizine in seasonal allergic rhino-conjunctivitis in children aged 6 to 12 years. Pediatr Allergy Immunol 1993;4: 47-52.
49. Ciprandi G, Tosca M, Passalacqua G, Canonica GW, Long- term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Ann Allergy Asthma Immunol 2001;87: 222-226.
50. Del Carpio J, Kabbash L, Turenne Y, Prevost M, Hebert J, Bedard PM, Nedilski M, Gutkowski A, Schulz J, Efficacy and safety of loratadine (10 mg once daily), terfenadine (60 mg twice daily), and placebo in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1989;84: 741-746.
51. Boner AL, Richelli C, Castellani C, Marchesi E, Andreoli A, Comparison of the effects of loratadine and astemizole in the treatment of children with seasonal allergic rhinoconjunctivitis. Allergy 1992;47: 98-102.
52. Frolund L, Etholm B, Irander K, Johannessen TA, Odkvist L, Ohlander B, Weeke B, A multicentre study of loratadine, clemastine and placebo in patients with perennial allergic rhinitis. Allergy 1990;45: 254-261.
53. Yang YH, Lin YT, Lu MY, Tsai MJ, Chiang BL, A double-blind, placebo-controlled, and randomized study of loratadine (Clarityne) syrup for the treatment of allergic rhinitis in children aged 3 to 12 years. Asian Pac J Allergy Immunol 2001;19: 171-175.
54. Okubo K, Gotoh M, Shimada K, Ritsu M, Okuda M, Crawford B, Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season. Int Arch Allergy Immunol 2005;136: 148-154.
55. Ngamphaiboon J, Direkwattanachai C, Visitsunthorn N, Vangveeravong M, Tiensuwan M, The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis. Asian Pac J Allergy Immunol 2005;23: 169-174.
56. Bachert C, Brostoff J, Scadding GK, Tasman J, Stalla-Bourdillon A, Murrieta M, Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. RIPERAN Study Group. Allergy 1998;53: 969-975.
57. Bachert C, Vovolis V, Margari P, Murrieta-Aguttes M, Santoni JP, Mizolastine in the treatment of seasonal allergic rhinoconjunctivitis: a European clinical experience with 5408 patients managed in daily practice (PANEOS SAR Study). Allergy 2001;56: 653-659.